Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y educación

Enviado por remote_content el Lun, 21/10/2024 - 08:43

Enfermedades infecciosas

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med.

Diciembre 2, 2020

Enfermedades infecciosas

Implications of Antibiotic Use During the COVID-19 Pandemic: The Example of Associated Antimicrobial Resistance in Latin America. Antibiotics

Marzo 20, 2021

Enfermedades infecciosas

Consensus recommendations based on evidence for abdominal sepsis in the pediatric and adult population of colombia. Infectio,

Julio 30, 2022

21 Octubre, 2024